# Aquestive Therapeutics Inc. (AQST) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $5.34, market value $670 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Aquestive Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 12.4×**. Each dollar of revenue is priced at 12.4×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -6.9%** (5-yr avg -14.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -97.5%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -188.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: 248.9%**. A 248.9% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 37.9%**. Return on all capital, debt included, is 37.9%: comfortably above what that capital costs.
- **Return on assets: -48.8%**. Each dollar of assets produces -48.8% of profit.

## Growth
- **Revenue growth (1 yr): -22.6%** (3-yr -2.2%/yr, 5-yr -0.6%/yr). Revenue fell 22.6% over the last year, against -0.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -52.9%**. Earnings per share fell 52.9%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 1.5×**. It would take 1.5 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 0.59**. A Z-score of 0.59 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Aquestive Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Aquestive Therapeutics Inc.; the consensus is strong_buy, with an average price target of $9.33 (+75% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 5.5%** (YTD -17.3%, 3-mo 35.9%). The shares are up 5.5% over twelve months including dividends.
- **From 52-week high: -29.3%** (82.3% above the low). Trading 29% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 70**. An RSI of 70 is neutral.
- **Beta (1 yr): 1.10** (volatility 81%). Beta of 1.10 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AQST · Page: https://foliofundamentals.com/stocks/aqst

Not investment advice.